Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidekatsu Yanai

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
International Journal of Molecular Sciences|November 11, 2022
Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease RiskHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Rinsho Byori. the Japanese Journal of Clinical Pathology|February 23, 2010
[Therapeutic application of diacylglycerol oil for the metabolic syndrome]Hidekatsu Yanai, Yoshiharu Tomono, Hiroshi Yoshida, et al.
Case Reports in Medicine|September 1, 2009
Myositis, Vasculitis, Hepatic Dysfunction in Adult-Onset Still's DiseaseHidekatsu Yanai, Nobuyuki Furutani, Hiroshi Yoshida, et al.
Cardiology Research|March 10, 2023
Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 DiabetesHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Sleep Medicine|July 25, 2017
Short sleep duration is associated with B-type natriuretic peptide levels and predicts the death of Japanese patients with type 2 diabetesHidetaka Hamasaki, Hisayuki Katsuyama, Akahito Sako, et al.
Journal of Clinical Medicine Research|May 1, 2018
Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin TherapyMariko Hakoshima, Hidekatsu Yanai, Kouki Kakuta, et al.
Journal of Clinical Medicine Research|October 24, 2025
Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 DiabetesHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Molecules (Basel, Switzerland)|January 8, 2025
Pathology and Treatments of Alzheimer's Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 DiabetesHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences|September 28, 2023
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and TreatmentsHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Metabolites|June 27, 2023
Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic PatientsHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
International Journal of Molecular Sciences|November 11, 2022
Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease RiskHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Rinsho Byori. the Japanese Journal of Clinical Pathology|February 23, 2010
[Therapeutic application of diacylglycerol oil for the metabolic syndrome]Hidekatsu Yanai, Yoshiharu Tomono, Hiroshi Yoshida, et al.
Case Reports in Medicine|September 1, 2009
Myositis, Vasculitis, Hepatic Dysfunction in Adult-Onset Still's DiseaseHidekatsu Yanai, Nobuyuki Furutani, Hiroshi Yoshida, et al.
Cardiology Research|March 10, 2023
Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 DiabetesHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Sleep Medicine|July 25, 2017
Short sleep duration is associated with B-type natriuretic peptide levels and predicts the death of Japanese patients with type 2 diabetesHidetaka Hamasaki, Hisayuki Katsuyama, Akahito Sako, et al.
Journal of Clinical Medicine Research|May 1, 2018
Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin TherapyMariko Hakoshima, Hidekatsu Yanai, Kouki Kakuta, et al.
Journal of Clinical Medicine Research|October 24, 2025
Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 DiabetesHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Molecules (Basel, Switzerland)|January 8, 2025
Pathology and Treatments of Alzheimer's Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 DiabetesHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences|September 28, 2023
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and TreatmentsHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Metabolites|June 27, 2023
Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic PatientsHidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Pageof 13